# A study of supplementation with Curcumin to Diabetics

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
27/04/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
14/06/2010	Completed	☐ Results
Last Edited	Condition category	Individual participant data
21/09/2010	Nutritional, Metabolic, Endocrine	<ul><li>Record updated in last year</li></ul>

## Plain English summary of protocol

Not provided at time of registration

# Contact information

## Type(s)

Scientific

#### Contact name

Prof Sun Changhao

#### Contact details

157 Baojian Road Nangang District Harbin China 150081 +86 (0)451 87502801 sun2002changhao@yahoo.com

# Additional identifiers

Protocol serial number 003

# Study information

#### Scientific Title

Supplementation with curcumin versus placebo treatment to lower blood glucose in diabetics: a randomised controlled trial

#### **Acronym**

CD

#### **Study objectives**

The function of curcumin in lowering blood glucose in diabetic patients.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Medical Ethics Committee of Public Health College, Harbin Medical University, approved on the 25th June 2009 (ref: 003)

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

**Treatment** 

## Health condition(s) or problem(s) studied

Diabetes mellitus

#### **Interventions**

We determine glucose and insulin with related blood indicators in a hospital. The drug name is Curcumin Qingtang tablet. The dosage given is 2.0 g/60 kg BW/d, equivalent Curcumin 300 mg/kg, take this drug orally for a month.

#### Intervention Type

Drug

#### Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Curcumin

#### Primary outcome(s)

Amended as of 21/09/2010:

- 1. Lipids (triglycerides [TG], total cholestrol [TC], low-density liporotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C])
- 2. Free fatty acids (FFAs)
- 3. Lipoprotein lipase (LPL)
- 4. Adipocyte fatty acid-binding protein (AFABP)
- 5. Liver ultrasonography
- 6. HbA1c
- 7. Apolipoproteins (ApoA1/ApoB)
- 8. Triacylglycerol

- 9. Cholesterol
- 10. 2-hour post-prandial glucose
- 11. Homeostasis model assessment insulin resistance (HOMA-IR)

#### Initial information at time of registration:

- 1. Glucose
- 2. Insulin

#### Key secondary outcome(s))

Amended as of 21/09/2010:

- 1. Age
- 2. Body mass index (BMI)
- 3. Diabetes duration
- 4. Cigarette use
- 5. Physical activity level
- 6. Food Frequency Questionnaire (FFQ)

#### Initial information at time of registration:

- 1. Red blood cell
- 2. White blood cell
- 3. Haemoglobin
- 4. Total protein
- 5. Albumin
- 6. Urea nitrogen
- 7. Creatinine
- 8. Alanine transaminase
- 9. Aspartate transaminase
- 10. Platelet count
- 11. Height
- 12. Weight
- 13. Waist circumference
- 14. Hip circumference
- 15. Blood pressure

#### Completion date

30/07/2009

# **Eligibility**

#### Key inclusion criteria

- 1. Type 2 diabetes mellitus; the condition of patients are stable
- 2. Fasting blood glucose greater than or equal to 7.8 mmol/L or postprandial blood glucose greater than or equal to 11.1 mmol/L
- 3. Aged 18 65 years, both male and female

#### Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

18 years

#### Sex

All

#### Key exclusion criteria

- 1. Type I diabetes
- 2. Pregnant or lactating women, or allergic to the tested samples
- 3. Have history of liver, kidney, hypertension, mental illness, taking other hypoglycaemics
- 4. People are uncooperative
- 5. Have diabetic ketosis, acidosis and infection in recent 3 months
- 6. Taking correlated medications which could potentially influence the purpose of this study
- 7. Failing to take drugs or the information is incomplete

#### Date of first enrolment

01/05/2009

#### Date of final enrolment

30/07/2009

## Locations

#### Countries of recruitment

China

## Study participating centre 157 Baojian Road

Harbin China 150081

# **Sponsor information**

#### Organisation

Public Health College - Harbin Medical University (China)

#### **ROR**

https://ror.org/05jscf583

# Funder(s)

#### Funder type

Research organisation

#### **Funder Name**

Amended as of 21/09/2010:

#### Funder Name

National Natural Science Foundation of China (NSFC) (China) and Canadian Institutes of Health Research (CIHR) (Canada) - China-Canada Joint Health Research Initiative (ref: 30810107)

#### Funder Name

Initial information at time of registration:

#### **Funder Name**

Development of Health Foods (China)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 No Yes